Trade Names:Lodrane- Liquid 4 mg brompheniramine/60 mg pseudoephedrine
Trade Names:Lodrane 12 D- Tablets 6 mg brompheniramine/45 mg pseudoephedrine
Trade Names:Lodrane LD- Capsules 6 mg brompheniramine/60 mg pseudoephedrine
Competitively antagonizes histamine at H 1 receptor sites.Pseudoephedrine
Causes vasoconstriction and subsequent shrinkage of nasal mucous membranes by alpha-adrenergic stimulation, which promotes nasal drainage.
Temporary relief of symptoms associated with seasonal and perennial allergic rhinitis and vasomotor rhinitis, including nasal congestion.
Hypersensitivity to any ingredients of product; nursing mothers, severe hypertension; severe coronary artery disease; narrow-angle glaucoma; urinary retention; peptic ulcer, asthma attack; MAOI therapy or for 2 wk after stopping MAOI therapy.
PO Lodrane extended-release tablet 1 or 2 tablets every 12 h. Lodrane liquid: 1 tsp (5 mL) every 4 to 6 h (max, 4 doses/24 h).Children 6 to 12 yr of age
PO Lodrane extended-release tablet: 1 tablet every 12 h. Lodrane liquid: ½ tsp (2.5 mL) every 4 to 6 h (max, 4 doses/24 h).Children 2 to 6 yr of age
PO Lodrane liquid: ¼ tsp (1.25 mL) every 4 to 6 h (max, 4 doses/24 h).Children less than 2 yr of age
PO Lodrane liquid: as recommended by health care provider.
Store tablets and liquid at 59° to 86°F. Protect tablets from light and moisture. Keep liquid tightly closed.
Effects may be enhanced by brompheniramine.Antacids
Rate of pseudoephedrine absorption may be increased.Antidepressants, antihypertensives
Do not use in patients receiving antidepressants or antihypertensive agents or within 14 days of stopping such treatment.Digitalis
Increased ectopic pacemaker activity can occur with pseudoephedrine.MAOIs (eg, isocarboxazid)
Do not use in patients receiving MAOI therapy or within 14 days of stopping such treatment. May prolong and intensify the effects of brompheniramine and increase the effects of pseudoephedrine.Mecamylamine, methyldopa, reserpine, veratrum alkaloids
Antihypertensive effects may be reduced by pseudoephedrine.Tricyclic antidepressants (eg, amitriptyline)
May prolong or intensify the anticholinergic effects of brompheniramine.
May interfere with diagnostic test results for skin tests using allergen extracts.
Palpitation; tachycardia; angina; elevated BP; circulatory collapse.
Drowsiness; confusion; restlessness; anorexia; dizziness; headache; insomnia; anxiety; tension; weakness; stimulation.
Nausea; vomiting; gastric distress; abdominal cramps.
Assess for allergy symptoms (eg, rhinitis, nasal congestion, sneezing, itching, watery eyes) before and periodically throughout therapy. Monitor patient for nervousness, dizziness, and insomnia. If noted hold therapy and notify health care provider.
Category C .
Lodrane extended-release tablets: Safety and efficacy in children less than 6 yr of age not established. Lodrane liquid: Safety and efficacy in children less than 2 yr of age not established.
More likely to cause dizziness, sedation, hyperexcitability, anticholinergic side effects (eg, urinary retention), confusion, hallucinations, seizures, CNS depression, and hypotension in the elderly.
Use with caution in patients with hypertension, heart disease, asthma, hyperthyroidism, increased intraocular pressure, diabetes mellitus, prostatic hypertrophy, bronchial asthma.
Pseudoephedrine is a CNS stimulant and has been abused.
Hallucination, convulsions and death, dizziness, sedation, hypotensionPseudoephedrine
Cardiac arrhythmias, cerebral hemorrhage, pulmonary edema, palpitations, tremor, dizziness, vomiting, fear, labored breathing, headache, dryness of mouth, pallor, weakness, panic, anxiety, confusion, hallucination, delirium.
Copyright © 2009 Wolters Kluwer Health.